One hundred students from four schools and high schools in Cantabria learn about the role of hospitals and the pharmaceutical industry in the development of a drug or how a patient can participate in a clinical trial.
Bringing science closer to schools, the program promoted by Farmaindustria in collaboration with research centers since 2016 has held this Friday a new meeting at the Marqués de Valdecilla University Hospital, in Santander, with a hundred students from four schools and institutes to learn about the process of research and development of new drugs in our country.
Students from IES José María Pereda, IES Cantabria, IES Santa Clara and Colegio Castroverde were able to learn first hand what the clinical research process consists of, from the scientific work until the drug reaches the patient.
Marcos López Hoyos, head of the Immunology Department at the Marqués de Valdecilla University Hospital and scientific director of the Valdecilla Health Research Institute (IDIVAL), explained why biomedical research is carried out in hospitals, while the director of Clinical and Translational Research at Farmaindustria, Amelia Martín Uranga, explained the process of developing, testing and marketing new drugs.
The Regional Minister of Education, Vocational Training and Universities, Sergio Silva, highlighted the “extraordinary pedagogical value” of this initiative to disseminate biomedical research.
The second objective of this program is to awaken vocations, and Enrique Ocio, head of the Hematology Department of the Marqués de Valdecilla Hospital and head of the Hematological Neoplasms and Hematopoietic Progenitor Transplantation Research Group of IDIVAL, spoke to the young people about this issue and the trajectory of the researchers.
The Value of Clinical Trials, Hope for Patients
The cornerstone of the research process is the clinical trial. This is the process used to test the safety and efficacy of new drugs and, on many occasions, the only therapeutic option for patients with serious diseases or for those who do not yet have treatment.
It is a complex process that requires 6-7 years of work and involves, together with the pharmaceutical company, authorities, researchers, hospitals and, of course, patients,” summarized Blanca Sánchez Santiago, coordinator of the Clinical Trials Unit at the Marqués de Valdecilla Hospital.
“Spain has become an international reference in clinical trials. And this leading position brings value to the Spanish healthcare system and society as a whole, since it attracts investment for hospitals, places healthcare professionals at the scientific forefront and provides opportunities for present and future patients, who can benefit from early access to new drugs through participation in trials,” said Martín Uranga.
Clinical trials are a source of hope for patients and their families and are studies conducted under strict regulations and rigorous ethical criteria, which ensure the protection of the patient at all times. Virginia Calderón, a patient participating in a clinical trial, told the students about her experience and the value of participating in these studies.
Bringing science to schools, which was created to contribute to the dissemination of biomedical research among high school students, visited the Marqués de Valdecilla Hospital for the second time after IDIVAL and Farmaindustria launched the program in this community just a year ago. After eight years in operation, the program has established itself as an activity of interest between the autonomous communities and the schools and institutes.
One hundred students from four schools and high schools in Cantabria learn about the role of hospitals and the pharmaceutical industry in the development of a drug or how a patient can participate in a clinical trial. Bringing science closer to schools, the program promoted by Farmaindustria in collaboration with research centers since 2016 has […]
Registrations are open for the seminar that will delve into the types, uses and ethical issues of generative artificial intelligence.
Next Monday March 11 will be held the training course called ‘How to improve your workflows with generative AI in basic and/or clinical research’ which will take place in the afternoon (16h to 20h) in the conference room third floor of IDIVAL.
The objectives of the workshop will be focused on obtaining resources to use artificial intelligence on a daily basis, knowing when to use it, as well as learning how to obtain efficient and satisfactory answers or knowing its limits and strengths of the different types.
The workshop will be limited to 25 students who will have to bring their laptop computer and answer an anonymous survey in this link: https://shre.ink/rQoq
Registrations are already open and can be made at the following link: https://forms.gle/1JhktYeHXMvQ43xm6
The course will be taught by Álvaro Díaz, Assistant of the Digestive Service of the Marqués de Valdecilla University Hospital (HUMV), Javier Pazó, IA Expert of the Spanish Foundation for the Study of the Liver (FEEH) and Juan Turnes, Head of the Digestive Service. University Hospital of Pontevedra.
Programme:
Registrations are open for the seminar that will delve into the types, uses and ethical issues of generative artificial intelligence. Next Monday March 11 will be held the training course called ‘How to improve your workflows with generative AI in basic and/or clinical research’ which will take place in the afternoon (16h to 20h) in […]
Clinical trials, industrial property or human factor engineering will be key topics to be discussed with the students.
The Valdecilla Health Research Institute (IDIVAL) participates in the Master’s Degree in Health Services Management of the University of Cantabria (UC), whose objective is to train professionals capable of leading processes of change and innovation in health systems.
The postgraduate course is made up of seven different modules and IDIVAL leads the block focused on health research within the module ‘Health Research. Public Health’. Classes will be held from February 16 to March 1 on a wide variety of topics.
Firstly, IDIVAL will talk about human factor engineering and medical technologies showing their current relevance in the bio-health field. The block will continue to delve into the role of scientific-technical platforms within health institutes, research with human biological samples and the role of hospital biobanks. Clinical trials will also be a key topic to be dealt with by Valdecilla’s Clinical Trials Unit, which will detail the steps involved in managing the clinical trial approval process and the necessary contracts.
The IDIVAL Management Department will also explain the IDIVAL model, the framework and sources of funding, as well as the institute’s research and innovation management. It will also address the national science and technology strategy, health innovation strategies and the strategic plan of a health research institute such as IDIVAL.
With regard to scientific activity, there will be a discussion on its evaluation, the good clinical practices that are necessary, in addition to dealing with concepts such as innovation and industrial protection in the healthcare environment.
With an eye on Europe, emphasis will be placed on the general framework of health policy in the European Union, with special mention of the Horizon Europe program with some practical cases and showing IDIVAL’s experience in this field.
Blended and cross-disciplinary training
The Master in Management and Administration of Health Services of the University of Cantabria (MADGS) is aimed at university graduates, graduates and university graduates, students in their final years, health professionals, as well as people interested in specializing in this professional field. It is also aimed at non-health professionals with an interest in this field.
The postgraduate course takes place between October 2023 and June 2024 and is compatible with the professional activity as it is blended learning. The face-to-face classes are held at the Faculty of Economics and Business Studies on Fridays (16:30 to 21:00 hours) and Saturdays (9:00 to 14:00 hours). Virtual classes are available through the Virtual Classroom Moodle of the University of Cantabria.
The complete master’s degree consists of seven modules plus the Final Project, although it is also possible to obtain the University Diploma of Specialization by taking only the last three modules plus the final project.
The modules are offered and can be taken individually and independently as Expert University Diplomas.
Modules and dates:
III. Public Management, Contracting and Competence Framework of Health Care Managers. 12/01/2024 to 10/02/2024
VII. Management of Health Services Provision. Primary Care Management and Hospital Management. 24/05/2024 to 07/06/2024
Final Program Work
Clinical trials, industrial property or human factor engineering will be key topics to be discussed with the students. The Valdecilla Health Research Institute (IDIVAL) participates in the Master’s Degree in Health Services Management of the University of Cantabria (UC), whose objective is to train professionals capable of leading processes of change and innovation in health […]
On the occasion of the World Day for Rare Diseases on February 29th, the Valdecilla Institute for Health Research (IDIVAL) will hold an event entitled ‘Update day on Rare Diseases and the need for a multiprofessional approach (360)´.
It will be a day where they will talk about rare diseases nowadays, the different treatments available and the perspectives to be taken into account such as rehabilitation, the expectations and aspirations of patients and the future vision of the Regional Ministry of Health of Cantabria.
It will take place in the Dr. Gómez Durán Assembly Hall of the Marqués de Valdecilla University Hospital. Admission will be free, although for logistical reasons it is suggested to send an e-mail before February 20 to enfraras360@gmail.com expressing interest in attending.
It is organized by José A. Riancho, Domingo González-Lamuño and José L. Fernández Luna, researchers from the Internal Medicine, Pediatrics and Genetics Services of HUMV and also IDIVAL researchers.
In addition, It has the collaboration of the companies Sanofi, Nutricia and Takeda.
On the occasion of the World Day for Rare Diseases on February 29th, the Valdecilla Institute for Health Research (IDIVAL) will hold an event entitled ‘Update day on Rare Diseases and the need for a multiprofessional approach (360)´. It will be a day where they will talk about rare diseases nowadays, the different treatments available […]
Previous hypertension, diabetes and renal insufficiency could alter plasma markers
A multidisciplinary research team belonging to the Neurodegenerative Diseases Group of IDIVAL and the Cognitive Impairment Unit of the Neurology Service of the Marqués de Valdecilla University Hospital (HUMV) has conducted a study aimed at understanding how different physiological variables and previous diseases could influence the early diagnosis of Alzheimer’s disease. The Clinical Analysis and Biochemistry Service and the Immunology Service of the HUMV have also collaborated in the research.
The research was carried out on 208 cognitively healthy volunteers from the Valdecilla Cohort by analyzing different markers in plasma and cerebrospinal fluid. This procedure is a simple, reliable and minimally invasive way to identify variables prior to observing the first memory failures characteristic of the disease.
The markers are two proteins called β-amyloid (forms β-40 and β-42), the ratio between them that biologically defines the disease and, finally, the protein called phosphorylated tau (p-tau181). In addition, these markers have been related to multiple variables such as blood pressure, liver enzymes, renal filtration or different cardiovascular risk factors.
Likewise, prior diagnosis of hypertension and diabetes may also have an effect on plasma amyloid and tau protein levels.
The aim is to understand the dynamics of plasma markers in the preclinical stages of Alzheimer’s disease with the intention of using them in the future as a population screening tool and to be able to look for preventive treatments. This is especially important now that the first disease-modifying drugs are in the process of being approved in Europe.
The study has been published in the prestigious International Journal of Molecular Sciences.
Reference: Martínez-Dubarbie, F.; Guerra-Ruiz, A.; López-García, S.; Irure-Ventura, J.; Lage, C.; Fernández-Matarrubia, M.; Pozueta-Cantudo, A.; García-Martínez, M.; Corrales-Pardo, A.; Bravo, M.; et al. Influence of Physiological Variables and Comorbidities on Plasma Aβ40, Aβ42, and p-tau181 Levels in Cognitively Unimpaired Individuals. Int. J. Mol. Sci. 2024, 25, 1481. https://doi.org/10.3390/ijms25031481
Previous hypertension, diabetes and renal insufficiency could alter plasma markers A multidisciplinary research team belonging to the Neurodegenerative Diseases Group of IDIVAL and the Cognitive Impairment Unit of the Neurology Service of the Marqués de Valdecilla University Hospital (HUMV) has conducted a study aimed at understanding how different physiological variables and previous diseases could influence […]
portal point to a high visibility of IDIVAL authors with more than 62,000 citations of articles published in the period 2018-2022. In this way, the Valdecilla brand exceeds 280,000 citations since its creation.
Of note in the period 2018-22 are the citations of papers published in the areas of Immunology (1,383 citations), Pharmacology (1,307 citations) and Oncology (1,134 citations) and as the origin of the citations Spain, United States, Italy and England.
The IDIVAL researchers most cited in the publications of this period have been:
|
Author |
Citations |
| Blanco Alonso, Ricardo (S. Reumatología, HUMV) | 3.535 |
| Durán Martínez, Ignacio (S. Oncología, HUMV) | 2.982 |
| Rodríguez Rodríguez, Eloy Manuel (S. Neurología, HUMV) | 1.941 |
| Rivera Herrero, Fernando (S. Oncología, HUMV) | 1.929 |
| Crespo García, Javier (S. Digestivo, HUMV) | 1.766 |
| Hernández Hernández, José Luís (S. Medicina Interna, HUMV) | 1.486 |
| López Hoyos, Marcos (S. Inmunología, HUMV) | 1.339 |
| Corrales Martínez, Alfonso Fernando (S. Reumatología, HUMV) | 1.088 |
| de la Torre Hernández, José María (S. Cardiología, HUMV) | 1.034 |
| Ocio San Miguel, Enrique María (S. Hematología, HUMV) | 973 |
The 5 articles published in this period 2018-2022 most cited have been collaborative studies conducted on patients, published in high impact journals:
portal point to a high visibility of IDIVAL authors with more than 62,000 citations of articles published in the period 2018-2022. In this way, the Valdecilla brand exceeds 280,000 citations since its creation. Of note in the period 2018-22 are the citations of papers published in the areas of Immunology (1,383 citations), Pharmacology (1,307 citations) […]
Meeting of the Ethics Committee for Research involving Medicines and Medical Devices
Meeting of the Ethics Committee for Research involving Medicines and Medical Devices
Meeting of the Ethics Committee for Research involving Medicines and Medical Devices
Meeting of the Ethics Committee for Research involving Medicines and Medical Devices
Meeting of the Ethics Committee for Research involving Medicines and Medical Devices
Meeting of the Ethics Committee for Research involving Medicines and Medical Devices
Meeting of the Ethics Committee for Research involving Medicines and Medical Devices
Meeting of the Ethics Committee for Research involving Medicines and Medical Devices
